insulin degludec

This page shows the latest insulin degludec news and features for those working in and with pharma, biotech and healthcare.

Sanofi launches insulin combo Soliqua in US

Sanofi launches insulin combo Soliqua in US. Diabetes drug available in pharmacies for $127 per 300 unit pen ahead of Novo Nordisk's Xultophy. ... Soliqua (insulin glargine/lixisenatide) reaches the market ahead of Novo Nordisk's rival combination

Latest news

Lilly and Boehringer launch first Lantus clone Basaglar in US

Nordisk's Levemir (insulin detemir) and Tresiba (insulin degludec). ... We know that starting insulin can be a challenging experience for some people with type 2 diabetes.".
FDA clears rival diabetes combos from Sanofi and Novo Nordisk

day. Both products include a long-acting basal insulin coupled with a GLP-1 agonist and are intended for the treatment of patients with type 2 diabetes who are not managing ... In the case of Xultophy, the combination is based on Novo's basal insulin
Novo Nordisk to cut 1,000 jobs as diabetes competition builds

momentum for its new basal insulin product Tresiba (insulin degludec). ... 1bn (2.86bn) brought in by Sanofi's established blockbuster Lantus (insulin glargine) during the same period.
Sanofi trumpets new IGlarLixi data after regulatory delay

Sharp increases in blood glucose after meals can contribute to insulin resistance, decrease insulin production and according to some studies increase the risk of vascular complications. ... Novo Nordisk's IDeglira/Xultophy (insulin degludec/liraglutide)
Jørgensen named Novo CEO-in-waiting as Sørensen plans retirement

Novo recently overtook Sanofi to become the leader in diabetes, but is facing increasing competition in the market from biosimilar insulin products, as well as downward pressure on pricing that has ... Delays to some key new products such as basal

More from news
Approximately 13 fully matching, plus 56 partially matching documents found.

Latest Intelligence

Interview: Peter Meeus, Novo Nordisk

Vice president sales and marketing, Novo Nordisk. International marketing manager insulin analogues, Novo Nordisk. ... Not reporting it is a very big issue.”. Novo has attempted to address hypoglycaemia with the launch of its new insulin Tresiba

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Medical Writer - (London, Brighton or Copenhagen): Competitive

Senior Programme Executive: Salary TBC

Science writer, Healthcare Brand Communications, London, £45-50K...: £45-50K

Senior Medical Writer: Great salary and benefits

Senior Account Manager or AD - Medical Communications: Salary TBC

HOME BASED Senior Account Executive / Account Manager - Medical ...: Salary TBC

Account Manager – Med Comms – London: Salary TBC

Senior / Principal Regulatory Writer – Home Working - UK or US: HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS

Editor – Medical Education Agency – Bucks: Salary TBC

Senior Medical Writer: Great salary and bebefits

Editorial Team Leader or Scientific Director: £50, 000 - £55, 000 benefits

Head of Operations/ BUD, Healthcare PR, London – Excellent leade...: Excellent Package

Digital Senior Account Director – Healthcare Advertising – Londo...: Salary TBC

Senior Medical Writer, Medical Communications, Relocate to Cardi...: Excellent Salary

Account Director - Global Healthcare Advertising (Digital) - Lon...: £55000 - £65000

FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...: EXCELLENT DAY RATES AVAILABLE

FREELANCE Account Manager – Creative Healthcare Advertising – Lo...: SUPERB DAY RATES AVAILABLE

Engagement Strategist, Healthcare Brand Communications, London, ...: Circa £60K

Account Manager, Healthcare PR: £40, 000 – £42, 000 great benefits and bonuses

Scientific Director: Great salary and bebefits

Senior Account Manager / Account Director: Great salary and bebefits

Senior Account Manager – Med Comms – Kent: Salary TBC

Editorial Director – Medical Education – Oxford: Negotiable

Principal Medical Writer, Medical Communications, Relocate to Ca...: Excellent Salary

Editor > Senior Editor – Medical Education – London: Very competitive with excellent benefits

Subscribe to our email news alerts

PMHub

Add my company

Solaris Health

The beauty of detail: an effective, compelling medical communications campaign requires each component to be carefully planned, expertly crafted and...

Latest intelligence

Pharma’s isolated islands of innovation: With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit: What does it mean for the life science sector?...
The Holy Grail of HCP Access: This is the data you need to gain access....